Medical Disclaimer This article is for informational purposes only and does not constitute medical advice
The first generation of GLP-1 therapies exhibit reduced susceptibility to enzymatic degradation, while providing effective glucose control, improved -cell function, body weight loss and decreased systolic blood pressure in patients with T2D (Meier, 2012) The newly developed incretin mimetics, including albiglutide, dulaglutide and semaglutide, are designed to have extended pharmacokinetic profiles and efficacy suitable once-weekly administration
If nausea persists beyond 8 weeks despite dietary adjustments, contact your healthcare provider to discuss dose timing or other options
But notice the problem at higher doses: 1.7mg requires more than 1ml, and 2.4mg requires 1.44ml
*Available for weight management patients How Henry Works Get started with no insurance required